WEBINAR VIDEO | What do the CJEU’s decisions on parallel trade of medicines mean for your company?
At this additional Christmas edition, the IP specialists in our Life Sciences team discuss the CJEU’s latest decisions on the parallel trade of medicines, and what these decisions mean in practice for your company.
On 17 November 2022, the CJEU delivered essentially two decisions on the parallel trade of medicines. The first concerned the rebranding of generic medicines to the branded reference medicine (in joined cases C-253/20 and C-254/20), and about which we published a blog on 24 November 2022. The second addressed the impact of anti-tampering devices on the possibility, and objective necessity, to rebox (in C-224/20 and C-147/20), and about which we published a blog on 2 December 2022.
Contact
Recommended articles
The new Belgian government’s public health policy: 10 key take-aways for pharma policy
The new Belgian federal government has outlined its vision for public health in a policy paper under the slogan “More money for health, more health for our money”. Public health is a high-priority sector with a significant budget, and the policy paper introduces several key measures that will shape the pharmaceutical industry in the coming years. For pharma companies operating in Belgium, these developments bring both new regulatory challenges and strategic opportunities. Here is a focused analysis of ten key changes and their potential impact on the pharma industry.
Read on
CJEU’s DocMorris Ruling: where is the line for pharmaceutical advertising?
The intersection of pharmaceutical advertising, consumer protection, and internal market freedoms remains a complex legal battleground within the EU. In Apothekerkammer Nordrhein v. DocMorris NV (C-517/23), the Court of Justice of the European Union (CJEU) revisited the meaning of ‘advertising of medicinal products’, clarifying how far national restrictions on pharmaceutical advertisements can go under EU pharmaceutical law and internal market principles.
Read on
New year, new policy: CPVO updates its public access to documents policy
The Community Plant Variety Office (CPVO) recently revised its public access to documents policy to align with the European Union (EU)’s evolving transparency standards. Effective since 15 January 2025, the new policy seeks to ensure broad access to all documents that the CPVO holds, while protecting private parties’ commercial interests. In particular, a system of prior confidentiality requests has been put in place for applicants of Community plant variety rights (CPVR).
Read on